AI evidence summary · MVP
Tribulus Terrestris for Erectile Dysfunction
AI preliminary evidence assessment
UU Below grading threshold
This preliminary assessment is currently available in Traditional Chinese.
Exact question對有勃起功能障礙的成人男性,口服單一蒺藜(Tribulus terrestris)製劑相較安慰劑或其他條件相同的同期對照,是否改善勃起功能及性功能量表,並有哪些不良反應?不同病因、製劑與共同治療分層呈現。
已驗證評讀顯示研究結果方向不一致。主要限制包括:三篇直接試驗僅有摘要;兩篇官方全文途徑不可得。兩篇回顧的資料為已封存原始內容的選定逐字全文片段及相關表格,並非完整文章存取;三個試驗事件依製劑、族群及招募時序推論區分,不能證明個人完全不重疊;不加總為獨特受試者人數。 整體 U 是既有規則對評級不確定性的處理:分數落在 D 區間,但 D 要求 E1–E3,實際為 E6;這不表示沒有人體研究,也不覆寫研究的正反結果。
Why this assessment was given
- 已驗證評讀顯示研究結果方向不一致。主要限制包括:三篇直接試驗僅有摘要;兩篇官方全文途徑不可得。兩篇回顧的資料為已封存原始內容的選定逐字全文片段及相關表格,並非完整文章存取;三個試驗事件依製劑、族群及招募時序推論區分,不能證明個人完全不重疊;不加總為獨特受試者人數。
Limitations affecting this assessment
- 三篇直接試驗均僅有摘要;無法完整核對分配隱藏、選擇性報告、退出原因、資助及利益衝突。
- 直接試驗追蹤僅30天至3個月,無法判定療效持續性、長期或罕見不良反應。
- 製劑標準化、劑量、族群與量表不同;IIEF、IIEF-5及各性功能領域不能直接互換,臨床重要性仍不確定。
- 三個試驗事件由方案、族群及時序推論區分,未證實參與者完全不重疊,故不加總唯一參與人數。
- 回顧可能重複收錄既有試驗;兩篇僅提供全文節錄,另一篇僅摘要,不能視為完整文章查核。
- 此背景讀者事實的必要欄位缺少足夠來源支持,因此未列為讀者研究結果,也未納入評級;同來源其他可驗證資訊仍分開保留。
- 研究使用國際勃起功能指數(IIEF)或其五題版(IIEF-5)問卷;不同版本、性功能領域與療程不能混成同一效應。2017年試驗的2.70分組間差未在摘要中明確界定為哪一領域,不能自行標為IIEF-5或整體15題總分。
- 2025年統合分析摘要報告安慰劑對照的IIEF-5平均差3.23分(95%信賴區間1.89至4.58)、IIEF-15平均差14.44分(5.75至23.14),方向有利於蒺藜;另列組內前後IIEF-5平均差4.21分,不能當成安慰劑對照效果。其納入表未取得,8項研究不是已確認8個獨立、成人單方蒺藜試驗;混方是否納入此統合池未能核實。
- 2026年廣泛草藥回顧的蒺藜次群標準化平均差0.74(95%信賴區間−0.24至1.72),未達統計顯著;表中包含混方,不能當成本題純單方效應。回顧作者指出不良事件描述不足,無法評估。
- 安全個案僅提供訊號:陰莖異常勃起個案及與atorvastatin同用後橫紋肌溶解個案缺乏同期對照、製劑及病因資訊,不能判定因果或發生率;短期試驗摘要未完整報告不良事件也不能排除罕見、長期或交互作用風險。
- 機構立場欄位使用既有資料中的廣義勃起功能障礙補充品及運動補充品評述;Mayo/Harvard等資料的範圍不能解讀為機構已用蒺藜單方人體試驗證明無效。此欄位是機構立場的權重,與直接試驗的混合臨床結果分開。
- 2025年單方蒺藜回顧對Santos試驗的改善及劑量敘述,與原始摘要的800毫克/日、30天及組間未顯著結果不一致;本頁採原始研究可核實的結果,不把回顧重述當成另一個獨立確認。
- 本次外部證據資料庫資料缺失,系統性回顧也未被納入該計分欄位;兩個欄位各依原規則採0.5中性政策值。這些值不是研究支持票,也不表示文獻中沒有系統性回顧。
- 三篇直接試驗僅有摘要;兩篇官方全文途徑不可得。兩篇回顧的資料為已封存原始內容的選定逐字全文片段及相關表格,並非完整文章存取。
- 三個試驗事件依製劑、族群及招募時序推論區分,不能證明個人完全不重疊;不加總為獨特受試者人數。
- IIEF、IIEF-5與各性功能領域、30天、12週及3個月不可混為同一效果;製劑及雄性素缺乏族群需分層。
- 組內量表或荷爾蒙改善不能建立相對安慰劑的療效;一篇直接試驗未提供可擷取的組間療效估計。
- 無藥物相關嚴重不良事件不等於無不良事件;三篇摘要均無可擷取不良事件數,資助亦未報告。
- 回顧不增加獨立試驗數。會議與後續論文可能引用同一試驗,參考文獻本身不能證明獨立世代。
- 依原摘要中方案、族群與招募時間推論三個不同試驗階段;未證明個別受試者完全不重疊,不可將研究人數合計解讀為不重複總參與者。
- U 的來源是原評級規則門檻,而非零人體證據;應以各試驗結果、族群及介入差異判讀。
Research results
Findings are currently provided in Traditional Chinese; source excerpts retain their original language.
Main result 1
30天30天IIEF-5由13.2至15.3,安慰劑由11.6至13.7;兩組隨時間皆改善,但組間無差異(p=.7914)。此劑量與時間未優於安慰劑,總睪固酮亦未呈現優勢。
Applicability assessment: 納入主訴勃起功能障礙、年滿40歲且未接受勃起功能障礙治療的男性;結果限於所研究製劑與30天療程。
- Population
- 年滿40歲、主訴勃起功能障礙的男性
- Intervention
- 蒺藜每日800 mg,分兩次服用
- Comparator
- 安慰劑,以相同方式服用
- Outcome
- IIEF-5勃起功能量表
- Follow-up
- 30天
- Formulation
- Not established
- Dose
- Tribulus terrestris 800 mg/day,分兩次,30天;萃取比例及皂苷標準化未報告。
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 2
12週12週ITT分析的IIEF分數變化組間差為2.70(95% CI 1.40–4.01),有利於Tribestan。性交滿意度、高潮功能、性慾、整體滿意度及GEQ亦有利於蒺藜;摘要未明確界定2.70估計的IIEF領域,不能改標為IIEF-5或IIEF-15總分效果。
Applicability assessment: 納入18至65歲輕至中度勃起功能障礙男性;結果對應研究所用的標準化Tribestan及12週療程。
- Population
- 18至65歲、輕至中度勃起功能障礙的男性
- Intervention
- 口服標準化蒺藜萃取物Tribestan,每日三次、每次兩錠
- Comparator
- 安慰劑
- Outcome
- IIEF分數變化
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- Tribestan 1500 mg/day:每錠250 mg乾燥草部萃取物(35–45:1),呋甾烷皂苷不少於112.5 mg;每日三次、每次兩錠、飯後服用。
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 3
3個月蒺藜組3個月IIEF-5由10.7至16.1,總睪固酮由2.2至2.7,兩項組內p<.001;未提供安慰劑組相應結果或可擷取組間療效對比,因此相對安慰劑效果不明。IPSS組內未顯著變化(14.4至14.6,p=.67)。
Applicability assessment: 納入有勃起功能障礙、下泌尿道症狀及部分雄性素缺乏的年長男性;摘要未提供蒺藜數值劑量。
- Population
- 有勃起功能障礙、下泌尿道症狀及部分雄性素缺乏的年長男性
- Intervention
- 蒺藜,每日三次
- Comparator
- 安慰劑
- Outcome
- 阿拉伯文版IIEF-5勃起功能量表分數
- Follow-up
- 3個月
- Formulation
- Not established
- Dose
- Tribulus terrestris每日三次、3個月;數值劑量、品牌及萃取標準化未於本摘要報告。
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 4
3個月此研究涵蓋勃起功能障礙患者、含蒺藜的口服多成分製劑及3個月追蹤。
Applicability assessment: 研究對象有勃起功能障礙,並使用安慰劑對照;介入品Tradamix含蒺藜及其他成分。
- Population
- 輕至中度勃起功能障礙患者
- Intervention
- 含海藻Ecklonia bicyclis、蒺藜及葡萄糖胺寡糖的Tradamix TX1000
- Comparator
- 安慰劑
- Outcome
- IIEF-15性功能量表
- Follow-up
- 3個月
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 5
12週兩組不良事件發生率未見差異,無藥物相關嚴重不良事件;摘要未提供事件種類、數量或停藥原因,不能說完全沒有不良事件。
Applicability assessment: 安全性資料來自使用標準化Tribestan的輕至中度勃起功能障礙男性。
- Population
- 輕至中度勃起功能障礙的男性
- Intervention
- 口服標準化蒺藜萃取物Tribestan
- Comparator
- 安慰劑
- Outcome
- 不良事件發生率及藥物相關嚴重不良事件
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- Tribestan 1500 mg/day:每錠250 mg乾燥草部萃取物(35–45:1),呋甾烷皂苷不少於112.5 mg;每日三次、每次兩錠、飯後服用。
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 6
13週追蹤此試驗比較勃起功能障礙患者使用兩種蒺藜萃取製劑。
Applicability assessment: 研究對象有勃起功能障礙,兩組都接受蒺藜製劑;比較的是不同商品。
- Population
- 勃起功能障礙患者
- Intervention
- EFFEX Tribulus蒺藜製劑
- Comparator
- Tribestan蒺藜製劑
- Outcome
- IIEF勃起功能領域分數
- Follow-up
- 13週追蹤
- Formulation
- Not established
- Dose
- Not established
Source excerpt: To compare the efficacy and safety of two herbal preparations (EFFEX Tribulus and Tribestan) based on Tribulus Terrestris herb dry extract in patients with ED.View source
Safety finding 7
3個月蒺藜組AST由26.5至27.8(p=.03);摘要亦稱總PSA上升、列值1.4及1.7(p=.007),但兩值皆標為before,時間標示不一致。這些是組內實驗室觀察,無組間安全對比、臨床不良事件數或停藥資料,不能據此確定臨床傷害或排除風險。
Applicability assessment: 實驗室安全性觀察來自同一群有勃起功能障礙及下泌尿道症狀的年長男性。
- Population
- 有勃起功能障礙及下泌尿道症狀的年長男性
- Intervention
- 蒺藜,每日三次
- Comparator
- 安慰劑
- Outcome
- 天門冬胺酸轉胺酶(AST)數值
- Follow-up
- 3個月
- Formulation
- Not established
- Dose
- Tribulus terrestris每日三次、3個月;數值劑量、品牌及萃取標準化未於本摘要報告。
Source excerpt: The mean of aspartate transaminase was elevated in group A after 3 months of receiving Tribulus terrestris (26.5 (before), 27.8 (after), respectively, p = 0.03).View source
Additional finding 8
此回顧討論勃起功能障礙替代療法及草藥的安慰劑對照試驗。
Applicability assessment: 系統性回顧涵蓋以IIEF評估勃起功能障礙的草藥試驗,並提及蒺藜。
- Population
- 主要診斷為勃起功能障礙的患者
- Intervention
- 替代療法與草藥,其中包括蒺藜
- Comparator
- 安慰劑對照試驗
- Outcome
- IIEF勃起功能量表
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 9
3個月此試驗評估含蒺藜的Icarifil多成分製劑用於勃起功能障礙患者。
Applicability assessment: 納入勃起功能障礙患者並測量IIEF-5,但Icarifil為含蒺藜的多成分製劑,且比較組涉及他達拉非。
- Population
- 勃起功能障礙患者
- Intervention
- 含蒺藜的Icarifil多成分製劑,單用或合併他達拉非
- Comparator
- Icarifil合併他達拉非,或單用他達拉非
- Outcome
- IIEF-5及SEP問卷
- Follow-up
- 3個月
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 10
3個月此試驗評估人參、蒺藜及L-精胺酸合用於勃起功能障礙患者的性功能。
Applicability assessment: 研究對象為勃起功能障礙男性,並以安慰劑對照;介入品同時含人參、蒺藜及L-精胺酸。
- Population
- 有勃起功能障礙的男性
- Intervention
- 人參、蒺藜及L-精胺酸合用製劑
- Comparator
- 安慰劑
- Outcome
- IIEF-5性功能量表
- Follow-up
- 3個月
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 11
此文系統性回顧蒺藜用於勃起功能障礙的研究,主要評估IIEF量表。
Applicability assessment: 系統性回顧與統合分析聚焦蒺藜及勃起功能障礙,並彙整既有研究。
- Population
- 勃起功能障礙患者
- Intervention
- 蒺藜
- Comparator
- 安慰劑
- Outcome
- IIEF-5或IIEF-15勃起功能量表
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 12
此回顧的蒺藜次群與對照組相比,勃起功能差異未達統計顯著。
Applicability assessment: 此回顧納入勃起功能障礙男性的草藥隨機試驗,表列蒺藜試驗並提供蒺藜次群分析。
- Population
- 有勃起功能障礙的男性
- Intervention
- 草藥膳食補充品;其中包含蒺藜試驗
- Comparator
- 安慰劑或無積極介入
- Outcome
- 勃起功能
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSources consulted
- Tribulus terrestris versus placebo in the treatment of erectile dysfunction: A prospective, randomized, double blind study. Abstract only · 2026-10-06T05:38:36.338381Z
- Alga Ecklonia bicyclis, Tribulus terrestris, and glucosamine oligosaccharide improve erectile function, sexual quality of life, and ejaculation function in patients with moderate mild-moderate erectile dysfunction: a prospective, randomized, placebo-controlled, single-blinded study. Context source; not counted as an included human-result report Abstract only · 2026-10-06T05:38:36.338381Z
- Evaluation of the efficacy and safety of Tribulus terrestris in male sexual dysfunction-A prospective, randomized, double-blind, placebo-controlled clinical trial. Abstract only · 2026-10-06T05:38:36.338381Z
- [Results of a comparative multi-center randomized clinical study of efficacy and safety of EFFEX Tribulus and Tribestan in patients with erectile dysfunction]. Context source; not counted as an included human-result report Abstract only · 2026-10-06T05:38:36.338381Z
- Tribulus terrestris versus placebo in the treatment of erectile dysfunction and lower urinary tract symptoms in patients with late-onset hypogonadism: A placebo-controlled study. Abstract only · 2026-10-06T05:38:36.338381Z
- Alternative medicine and herbal remedies in the treatment of erectile dysfunction: A systematic review. Context source; not counted as an included human-result report Abstract only · 2026-10-06T05:38:36.338381Z
- Icarifil® in Association with Daily Use of Tadalafil (5 mg) versus Standard Tadalafil Daily Dose (5 mg) or Alone: Results from a Controlled, Randomized Clinical Trial. Context source; not counted as an included human-result report Abstract only · 2026-10-06T05:38:36.338381Z
- The Effect of the Combination of Ginseng, Tribulus Terrestris, and L-arginine on the Sexual Performance of Men with Erectile Dysfunction: a randomized, double-blind, parallel, and placebo-controlled clinical trial. Context source; not counted as an included human-result report Abstract only · 2026-10-06T05:38:36.338381Z
- Tribulus terrestris for management of patients with erectile dysfunction: a systematic review and meta-analysis of randomized trials. Context source; not counted as an included human-result report Abstract only · 2026-10-06T05:38:36.338381Z
- Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis of randomized-controlled trials. Context source; not counted as an included human-result report Full-text excerpt · 2026-10-06T05:38:36.338381Z
Reading and assessment notes
Grade U means the project grading threshold was not met. It may result from a low score or a structural downgrade; it does not mean unverified evidence, no studies, or proven no effect. Read the scoring and threshold explanation.
Absence of reported harms does not establish safety. This summary does not provide individual treatment or dosing advice.
Data and assessment record
Search coverage for this case
對有勃起功能障礙的成人男性,口服單一蒺藜(Tribulus terrestris)製劑相較安慰劑或其他條件相同的同期對照,是否改善勃起功能及性功能量表,並有哪些不良反應?不同病因、製劑與共同治療分層呈現。
Searched:2026-10-06T05:38:36.338381Z · Databases:PubMed
41 records identified; 41 screened; 3 reports from 3 unique study populations included.
Some included reports were assessed without full text.
- 部分候選文獻未取得全文,完整偏倚風險與次要結果評讀受限。
- 系統檢索限於 PubMed;未涵蓋所有資料庫與完整引文追查。
Processing record
Evidence summary available
Sources through:2026-10-06 · Generated:2026-10-06T06:20:11.868263+00:00
Retrieved 41 records · Screened 41 · Included 3 reports · Omitted 38
Run:rating-candidate-final-v3
codex_cli / gpt-6.1-sol / problem-search-source-bound-l2+l11-v1
{
"included": 3,
"limits_hit": [
"fulltext_unavailable",
"limited_citation_tracing"
],
"omitted": 38,
"retrieved": 41,
"screened": 41
} sha256:1e5fe6cd6c308c71cd08434648a28594747702c6371d5e618b3e7ee34f8d1e85